{ "cells": [ { "cell_type": "code", "execution_count": 9, "metadata": {}, "outputs": [], "source": [ "from selenium import webdriver\n", "from selenium.webdriver.common.by import By\n", "from selenium.webdriver.support.ui import WebDriverWait\n", "from selenium.webdriver.support import expected_conditions as EC\n", "import csv\n", "\n", "\n", "from selenium import webdriver\n", "from selenium.webdriver.common.by import By\n", "from selenium.webdriver.support.ui import WebDriverWait\n", "from selenium.webdriver.support import expected_conditions as EC\n", "import csv\n", "\n", "# CSVファイルの保存設定\n", "output_file = \"search_results.csv\"\n", "\n", "# WebDriverを初期化\n", "driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n" ] }, { "cell_type": "code", "execution_count": 10, "metadata": {}, "outputs": [], "source": [ "def fetch_clinical_trials(disease_name=\"\", freeword=\"\"):\n", " \"\"\"\n", " 指定された対象疾患名およびフリーワード検索に基づいてjRCTから臨床試験情報を取得します。\n", "\n", " Args:\n", " disease_name (str): 対象疾患名（例: \"がん 神経膠腫 骨髄腫\"）\n", " freeword (str): フリーワード検索（例: \"免疫療法\"）\n", "\n", " Returns:\n", " list: 検索結果のリスト（[試験ID, タイトル, 対象疾患, 進捗状況, 日付, リンク]）\n", " \"\"\"\n", " # WebDriverを初期化\n", " driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n", "\n", " all_results = []\n", "\n", " try:\n", " # jRCTの検索ページにアクセス\n", " driver.get(\"https://jrct.niph.go.jp/search\")\n", "\n", " # 対象疾患名を入力\n", " if disease_name:\n", " disease_field = WebDriverWait(driver, 10).until(\n", " EC.presence_of_element_located((By.ID, \"reg-plobrem-1\"))\n", " )\n", " disease_field.send_keys(disease_name)\n", "\n", " # 対象疾患名の条件を「or」に設定\n", " condition_select = driver.find_element(By.ID, \"reg-plobrem-type\")\n", " condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n", "\n", " # フリーワード検索を入力\n", " if freeword:\n", " freeword_field = WebDriverWait(driver, 10).until(\n", " EC.presence_of_element_located((By.ID, \"demo-1\"))\n", " )\n", " freeword_field.send_keys(freeword)\n", "\n", " # フリーワード検索の条件を「or」に設定\n", " condition_select = driver.find_element(By.ID, \"others\")\n", " condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n", "\n", " # 募集中を選択\n", " recruitment_checkbox = driver.find_element(By.ID, \"reg-recruitment-2\")\n", " recruitment_checkbox.click()\n", "\n", " # 検索ボタンをクリック\n", " search_button = driver.find_element(By.NAME, \"button_type\")\n", " search_button.click()\n", "\n", " # ページネーション対応ループ\n", " while True:\n", " # 現在のページの結果がロードされるのを待機\n", " WebDriverWait(driver, 10).until(\n", " EC.presence_of_element_located((By.CSS_SELECTOR, \"table tbody tr\"))\n", " )\n", "\n", " # 現在のページの結果を取得\n", " rows = driver.find_elements(By.CSS_SELECTOR, \"table tbody tr\")\n", " for row in rows:\n", " columns = row.find_elements(By.TAG_NAME, \"td\")\n", " if len(columns) > 4:\n", " # 試験情報をリストに追加\n", " trial_id = columns[0].text\n", " title = columns[1].text\n", " condition = columns[2].text\n", " status = columns[3].text\n", " date = columns[4].text\n", "\n", " # リンクを取得（エラー処理を追加）\n", " try:\n", " link = columns[1].find_element(By.TAG_NAME, \"a\").get_attribute(\"href\")\n", " except Exception as e:\n", " link = \"リンク取得エラー\"\n", "\n", " all_results.append([trial_id, title, condition, status, date, link])\n", "\n", " # ページネーションの確認\n", " try:\n", " current_page = driver.find_element(By.CSS_SELECTOR, \"ul.pagination li.active\").text\n", " print(f\"{current_page} ページ目を処理しました。\")\n", " except Exception:\n", " print(\"ページネーションが存在しません。全ての結果を取得しました。\")\n", " break\n", "\n", " # 次ページボタンのリストを取得\n", " pagination_buttons = driver.find_elements(By.CSS_SELECTOR, \"ul.pagination li a\")\n", " next_button = None\n", " for button in pagination_buttons:\n", " if button.text.isdigit() and int(button.text) > int(current_page):\n", " next_button = button\n", " break\n", "\n", " if next_button:\n", " next_button.click()\n", " WebDriverWait(driver, 10).until(EC.staleness_of(rows[0])) # ページが変わるまで待機\n", " else:\n", " print(\"次のページはありません。全ての結果を取得しました。\")\n", " break\n", "\n", " finally:\n", " # ブラウザを閉じる\n", " driver.quit()\n", "\n", " return all_results\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [ "def create_dataframe_from_urls(urls):\n", " \"\"\"\n", " URLのリストを受け取り、pandas DataFrameを作成します。\n", " \"\"\"\n", " \n", " all_data = []\n", "\n", " for url in urls:\n", " print(f\"Processing URL: {url}\")\n", " # 各メソッドを使ってデータを取得\n", " purpose = scrape_study_purpose(url)\n", " design_details = scrape_jrct_details_with_english(url)\n", " additional_details = scrape_jrct_details(url)\n", "\n", " # 統合する\n", " data = {\"研究・治験の目的\": purpose, **design_details, **additional_details}\n", " all_data.append(data)\n", "\n", " # pandas DataFrameに変換\n", " return pd.DataFrame(all_data)" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "code", "execution_count": 11, "metadata": {}, "outputs": [], "source": [ "import pandas as pd\n", "import requests\n", "from bs4 import BeautifulSoup\n", "\n", "def scrape_study_purpose(url):\n", " \"\"\"\n", " 指定されたjRCT URLから研究・治験の目的を抽出します。\n", " \"\"\"\n", " response = requests.get(url)\n", " response.raise_for_status()\n", " soup = BeautifulSoup(response.text, 'html.parser')\n", "\n", " # \"研究・治験の目的\" を特定\n", " purpose_label = soup.find('label', text='研究・治験の目的')\n", " if purpose_label:\n", " # \"研究・治験の目的\" に対応するデータを取得\n", " purpose_td = purpose_label.find_parent('th').find_next_sibling('td')\n", " if purpose_td:\n", " return purpose_td.text.strip()\n", "\n", " return None\n", "\n", "\n", "def scrape_jrct_details_with_english(url):\n", " \"\"\"\n", " 指定されたjRCT URLから試験デザイン情報（日本語と英語の両方）を抽出します。\n", " \"\"\"\n", " response = requests.get(url)\n", " response.raise_for_status()\n", " soup = BeautifulSoup(response.text, 'html.parser')\n", "\n", " data = {\"URL\": url}\n", "\n", " # 試験デザイン項目（日本語と英語をペアで取得）\n", " design_labels = [\n", " ('試験の種類', 'Study Type'),\n", " ('無作為化', 'allocation'),\n", " ('盲検化', 'masking'),\n", " ('対照', 'control'),\n", " ('割付け', 'assignment'),\n", " ('研究目的', 'purpose')\n", " ]\n", "\n", " for label_jp, label_en in design_labels:\n", " label = soup.find('label', string=lambda text: text and label_jp in text)\n", " if label:\n", " # 日本語部分のtd\n", " td_jp = label.find_parent('th').find_next_sibling('td')\n", " # 英語部分のtd（次のtd要素）\n", " td_en = td_jp.find_next_sibling('td') if td_jp else None\n", "\n", " # データに日本語と英語を追加\n", " data[label_jp] = td_jp.text.strip() if td_jp else None\n", " data[label_en] = td_en.text.strip() if td_en else None\n", "\n", " return data\n", "\n", "\n", "def scrape_jrct_details(url):\n", " \"\"\"\n", " jRCTの指定URLから、必要な情報を抽出します。\n", " \"\"\"\n", " response = requests.get(url)\n", " response.raise_for_status()\n", " soup = BeautifulSoup(response.text, 'html.parser')\n", "\n", " data = {\"URL\": url}\n", "\n", " # 抽出項目とラベルの対応\n", " labels = [\n", " ('主たる選択基準', 'Inclusion Criteria'),\n", " ('主たる除外基準', 'Exclusion Criteria'),\n", " ('年齢下限', 'Age Minimum'),\n", " ('年齢上限', 'Age Maximum'),\n", " ('性別', 'Gender'),\n", " ('中止基準', 'Discontinuation Criteria'),\n", " ('対象疾患キーワード', 'Keyword'),\n", " ('介入の内容', 'Intervention(s)')\n", " ]\n", "\n", " for label_jp, label_en in labels:\n", " # 日本語ラベルを検索\n", " label = soup.find('label', string=lambda text: text and label_jp in text)\n", " if label:\n", " # 日本語部分のデータ\n", " td_jp = label.find_parent('th').find_next_sibling('td')\n", " # 英語部分のデータ\n", " td_en = td_jp.find_next_sibling('td') if td_jp else None\n", "\n", " # データに追加\n", " data[label_jp] = td_jp.decode_contents().strip().replace('
', '\\n') if td_jp else None\n", " data[label_en] = td_en.decode_contents().strip().replace('
', '\\n') if td_en else None\n", "\n", " return data\n", "\n", "\n", "def extract_jrct_links(results):\n", " \"\"\"\n", " fetch_clinical_trialsの結果からjRCT-Noを抽出し、詳細リンクを作成する。\n", "\n", " Args:\n", " results (list): fetch_clinical_trialsから得られる結果リスト\n", "\n", " Returns:\n", " list: jRCTの詳細ページリンクリスト\n", " \"\"\"\n", " base_url = \"https://jrct.niph.go.jp/latest-detail/\"\n", " links = []\n", " for result in results:\n", " if len(result) > 0:\n", " jrct_no = result[0] # jRCT-Noは結果リストの最初の要素\n", " links.append(base_url + jrct_no)\n", " return links\n", "\n", "\n", "def create_dataframe_from_urls(urls):\n", " \"\"\"\n", " URLのリストを受け取り、pandas DataFrameを作成します。\n", " \"\"\"\n", " all_data = []\n", "\n", " for url in urls:\n", " print(f\"Processing URL: {url}\")\n", " # 各メソッドを使ってデータを取得\n", " purpose = scrape_study_purpose(url)\n", " design_details = scrape_jrct_details_with_english(url)\n", " additional_details = scrape_jrct_details(url)\n", "\n", " # 統合する\n", " data = {\"研究・治験の目的\": purpose, **design_details, **additional_details}\n", " all_data.append(data)\n", "\n", " # pandas DataFrameに変換\n", " return pd.DataFrame(all_data)\n", "\n", "def reorder_columns(df):\n", " \"\"\"\n", " DataFrame の列を日本語の列を前半に、英語の列を後半に並び替える。\n", " \"\"\"\n", " # 日本語と英語の列を分ける\n", " jp_columns = [col for col in df.columns if all(ord(c) < 128 for c in col) is False] # 非 ASCII（日本語）文字列を含む列\n", " en_columns = [col for col in df.columns if col not in jp_columns] # 残りの列を英語と仮定\n", "\n", " # 日本語列 + 英語列の順序で整列\n", " ordered_columns = jp_columns + en_columns\n", "\n", " # 列を並び替えた DataFrame を返す\n", " return df[ordered_columns]" ] }, { "cell_type": "code", "execution_count": 12, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "ページネーションが存在しません。全ての結果を取得しました。\n" ] } ], "source": [ "# WebDriverを初期化\n", "driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n", "\n", "# fetch_clinical_trialsを使って検索結果を取得\n", "results = fetch_clinical_trials(disease_name=\"神経膠腫 骨髄腫\", freeword=\"\")" ] }, { "cell_type": "code", "execution_count": 13, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240141\n" ] }, { "name": "stderr", "output_type": "stream", "text": [ "/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_40777/81950631.py:14: DeprecationWarning: The 'text' argument to find()-type methods is deprecated. Use 'string' instead.\n", " purpose_label = soup.find('label', text='研究・治験の目的')\n" ] }, { "name": "stdout", "output_type": "stream", "text": [ "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240121\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1031240239\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240056\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021240013\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240090\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240014\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240003\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230660\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021230055\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2061230084\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230097\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230095\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011230049\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230108\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230069\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230223\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230065\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230087\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2032230060\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1070230005\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230009\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230007\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041220125\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220036\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2063220071\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220022\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033220220\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031220060\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051220019\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2053220006\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210635\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210607\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033210469\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210084\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210074\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210299\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011210025\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051210043\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031200320\n" ] }, { "ename": "HTTPError", "evalue": "403 Client Error: Forbidden for url: https://jrct.niph.go.jp/latest-detail/jRCTs031200320", "output_type": "error", "traceback": [ "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m", "\u001b[0;31mHTTPError\u001b[0m Traceback (most recent call last)", "Cell \u001b[0;32mIn[13], line 5\u001b[0m\n\u001b[1;32m 2\u001b[0m jrct_links \u001b[38;5;241m=\u001b[39m extract_jrct_links(results)\n\u001b[1;32m 4\u001b[0m \u001b[38;5;66;03m# 詳細リンクからデータフレームを作成\u001b[39;00m\n\u001b[0;32m----> 5\u001b[0m df \u001b[38;5;241m=\u001b[39m \u001b[43mcreate_dataframe_from_urls\u001b[49m\u001b[43m(\u001b[49m\u001b[43mjrct_links\u001b[49m\u001b[43m)\u001b[49m\n", "Cell \u001b[0;32mIn[11], line 125\u001b[0m, in \u001b[0;36mcreate_dataframe_from_urls\u001b[0;34m(urls)\u001b[0m\n\u001b[1;32m 123\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mProcessing URL: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00murl\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m 124\u001b[0m \u001b[38;5;66;03m# 各メソッドを使ってデータを取得\u001b[39;00m\n\u001b[0;32m--> 125\u001b[0m purpose \u001b[38;5;241m=\u001b[39m \u001b[43mscrape_study_purpose\u001b[49m\u001b[43m(\u001b[49m\u001b[43murl\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m 126\u001b[0m design_details \u001b[38;5;241m=\u001b[39m scrape_jrct_details_with_english(url)\n\u001b[1;32m 127\u001b[0m additional_details \u001b[38;5;241m=\u001b[39m scrape_jrct_details(url)\n", "Cell \u001b[0;32mIn[11], line 10\u001b[0m, in \u001b[0;36mscrape_study_purpose\u001b[0;34m(url)\u001b[0m\n\u001b[1;32m 6\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m 7\u001b[0m \u001b[38;5;124;03m指定されたjRCT URLから研究・治験の目的を抽出します。\u001b[39;00m\n\u001b[1;32m 8\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m 9\u001b[0m response \u001b[38;5;241m=\u001b[39m requests\u001b[38;5;241m.\u001b[39mget(url)\n\u001b[0;32m---> 10\u001b[0m \u001b[43mresponse\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mraise_for_status\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m 11\u001b[0m soup \u001b[38;5;241m=\u001b[39m BeautifulSoup(response\u001b[38;5;241m.\u001b[39mtext, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mhtml.parser\u001b[39m\u001b[38;5;124m'\u001b[39m)\n\u001b[1;32m 13\u001b[0m \u001b[38;5;66;03m# \"研究・治験の目的\" を特定\u001b[39;00m\n", "File \u001b[0;32m~/miniforge3/envs/gradio/lib/python3.12/site-packages/requests/models.py:1024\u001b[0m, in \u001b[0;36mResponse.raise_for_status\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m 1019\u001b[0m http_error_msg \u001b[38;5;241m=\u001b[39m (\n\u001b[1;32m 1020\u001b[0m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mstatus_code\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m Server Error: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mreason\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m for url: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39murl\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m 1021\u001b[0m )\n\u001b[1;32m 1023\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m http_error_msg:\n\u001b[0;32m-> 1024\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m HTTPError(http_error_msg, response\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m)\n", "\u001b[0;31mHTTPError\u001b[0m: 403 Client Error: Forbidden for url: https://jrct.niph.go.jp/latest-detail/jRCTs031200320" ] } ], "source": [ " # jRCT詳細リンクを作成\n", "jrct_links = extract_jrct_links(results)\n", "\n", " # 詳細リンクからデータフレームを作成\n", "df = create_dataframe_from_urls(jrct_links)" ] }, { "cell_type": "code", "execution_count": 20, "metadata": {}, "outputs": [], "source": [ "# 整列後の DataFrame を作成\n", "sorted_df = reorder_columns(df)" ] }, { "cell_type": "code", "execution_count": 25, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_36648/2325933109.py:1: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " sorted_df['JRCT ID'] = [result[0] for result in results]\n", "/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_36648/2325933109.py:2: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " sorted_df['Title'] = [result[1] for result in results]\n" ] } ], "source": [ "sorted_df['JRCT ID'] = [result[0] for result in results]\n", "sorted_df['Title'] = [result[1] for result in results]" ] }, { "cell_type": "code", "execution_count": 27, "metadata": {}, "outputs": [], "source": [ "new_order = [\"JRCT ID\", \"Title\"] + [col for col in sorted_df.columns if col not in [\"JRCT ID\", \"Title\"]]" ] }, { "cell_type": "code", "execution_count": 28, "metadata": {}, "outputs": [], "source": [ "sorted_df = sorted_df[new_order]" ] }, { "cell_type": "code", "execution_count": 29, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDTitle研究・治験の目的URL無作為化allocation盲検化masking対照control...性別Gender中止基準Discontinuation Criteria対象疾患キーワードKeyword介入の内容Intervention(s)試験の種類Study Type
0jRCT2051240141新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO...H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20...https://jrct.niph.go.jp/latest-detail/jRCT2051...無作為化比較randomized controlled trial二重盲検double blindプラセボ対照placebo control...None被験者は、ベースラインでONC201週2回投与群、ONC201週1回投与群又はプラセボ投与群...Participants will be randomized at baseline in...NaNNaN
1jRCT2051240121放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...https://jrct.niph.go.jp/latest-detail/jRCT2051...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...None薬物　アベマシクリブ\\n\\r\\n経口投与\\n\\r\\nその他の名称 LY2835219\\n\\r...Drug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r...NaNNaN
2jRCT1031240239JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学...手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を対象に、標準治...https://jrct.niph.go.jp/latest-detail/jRCT1031...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性Both＜患者の中止について＞\\n\\r\\n(1) プロトコール治療無効と判断\\n\\r\\n(2) 有害...NoneA群：標準治療群[術後化学放射線療法]/ B群：試験治療群[Watch &amp; Wait...Group A: Standard treatment group [Adjuvant ch...介入研究Interventional
3jRCT2041240056[M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する...再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。https://jrct.niph.go.jp/latest-detail/jRCT2041...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...None投与群：ABBV-383用量A\\n\\r\\nABBV-383の用量Aを151週間の試験期間中に...Experimental: ABBV-383 Dose A\\n\\r\\nParticipant...NaNNaN
4jRCT2021240013ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投...重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価することhttps://jrct.niph.go.jp/latest-detail/jRCT2021...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNoneサバトリマブ（MBG453）：静脈内投与\\n\\r\\nアザシチジン：皮下投与又は静脈内投与\\n...Sabatolimab (MBG453): Solution for intravenous...NaNNaN
5jRCT2031240090再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...https://jrct.niph.go.jp/latest-detail/jRCT2031...無作為化比較randomized controlled trial非盲検open(masking not used)無治療対照/標準治療対照no treatment control/standard of care control...男性・女性Both1）プロトコール治療無効と判断された場合（無効中止）\\n\\r\\n2）\\t有害事象によりプロト...None膠芽腫、grade 3・4星細胞腫、grade 3乏突起膠腫glioblastoma, grade3/4 astrocytoma, grade3 oli...A群：BPC療法\\n\\r\\n悪性神経膠腫に対して保険適用されている化学療法から患者の状態に合...Group A: BPC Therapy\\n\\r\\nDepending on the pat...NaNNaN
6jRCT2031240014自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患...本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並...https://jrct.niph.go.jp/latest-detail/jRCT2031...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneTeclistamab -\\n\\r\\nTeclistamab，ダラツムマブ皮下投与製剤及びレ...Teclistamab-Teclistamab, Daratumumab SC, Lenal...NaNNaN
7jRCT2041240003再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と...Treatmenthttps://jrct.niph.go.jp/latest-detail/jRCT2041...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNoneAZD0305 を3週毎に静脈内投与する\\nAZD0305 IV every 3 weeks\\nNaNNaN
8jRCT2031230660再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo...本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単...https://jrct.niph.go.jp/latest-detail/jRCT2031...非無作為化比較non-randomized controlled trial非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNonecevostamab：Cevostamabは、1サイクルを28日間として2週間隔、4週間隔に...cevostamab: Cevostamab will be administered in...NaNNaN
9jRCT2021230055CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ...再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法...https://jrct.niph.go.jp/latest-detail/jRCT2021...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneエルラナタマブ（投与経路：皮下）\\n\\r\\nエロツズマブ（投与経路：静脈内）\\n\\r\\nポマ...Drug: Elranatamab\\n\\r\\nElranatamab will be adm...NaNNaN
10jRCT2061230084自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca...自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法...https://jrct.niph.go.jp/latest-detail/jRCT2061...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneA群\\n\\r\\n製品：イデカブタゲン　ビクルユーセル\\n\\r\\n規定用量を規定された日に投与...ArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n...NaNNaN
11jRCT2071230097再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480...https://jrct.niph.go.jp/latest-detail/jRCT2071...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNone[日本人コホート] \\n\\r\\nMezigdomide/ボルテゾミブ/デキサメタゾン\\n\\r...[Japan safety lead-in cohort]\\n\\r\\nMezigdomide...NaNNaN
12jRCT2071230095再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ...https://jrct.niph.go.jp/latest-detail/jRCT2071...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneA群：Mezigdomide、カルフィルゾミブ、デキサメタゾン\\n\\r\\nB群：カルフィルゾ...Arm A: Mezigdomide, Carfilzomib and Dexamethas...NaNNaN
13jRCT2011230049未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､...未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab...https://jrct.niph.go.jp/latest-detail/jRCT2011...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNone治験治療、自家末梢血幹細胞採取および移植、血液検査、骨髄検査等Study treatment,Autologous Peripheral Blood St...NaNNaN
14jRCT2051230108再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93...再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。https://jrct.niph.go.jp/latest-detail/jRCT2051...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNoneCC-93269CC-93269NaNNaN
15jRCT2051230069神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...https://jrct.niph.go.jp/latest-detail/jRCT2051...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性Both1) 投与継続が困難な有害事象が発現した場合\\t\\n\\r\\n2) 治験開始後...None＜コホート1＞\\n\\r\\nロムスチン130 mg/m2を6週間ごとに経⼝投与する。\\n\\r\\...&lt;cohort1&gt;\\n\\r\\nLomustine 130 mg/m2 orall...NaNNaN
16jRCT2031230223新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe...新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ...https://jrct.niph.go.jp/latest-detail/jRCT2031...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneA1群: Iberdomide 用量 1レベル\\n\\r\\nA2群: Iberdomide 用...Arm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom...NaNNaN
17jRCT2051230065多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性...パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を...https://jrct.niph.go.jp/latest-detail/jRCT2051...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneパート1:\\n\\r\\n被験薬：Belantamab\\n\\r\\n被験薬：ベランタマブ　マホドチ...Part1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant...NaNNaN
18jRCT2031230087再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特...・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54...https://jrct.niph.go.jp/latest-detail/jRCT2031...非無作為化比較non-randomized controlled trial非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNone被験薬: REGN5458静脈内投与\\n\\r\\n第II相: 疾患進行が認められるまで、又はそ...Drug: REGN5458 administered by intravenous (IV...NaNNaN
19jRCT2032230060初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...https://jrct.niph.go.jp/latest-detail/jRCT2032...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性Both以下のいずれかの場合、プロトコール治療（テモゾロミド維持療法6サイクル及びHeadG2）を中...None神経膠腫Glioma本品を使用する患者は、頭髪をすべて剃り、TTF ジェネレーターに接続した４枚のINE トラン...The patient using the product should shave all...NaNNaN
20jRCT1070230005迅速ウイルスPCR法によるウイルス感染症の早期診断ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1...https://jrct.niph.go.jp/latest-detail/jRCT1070......男性・女性BothNone白血病、悪性リンパ腫、多発性骨髄腫、再生不良性貧血、骨髄異形成症候群Leukemia, malignant lymphoma, multiple myeloma...観察研究Observational
21jRCT2031230009先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ...本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による...https://jrct.niph.go.jp/latest-detail/jRCT2031...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNone薬剤：イサツキシマブ IV（SAR650984）\\n\\r\\n　剤形：バイアル、投与経路：静脈...Drug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace...NaNNaN
22jRCT2031230007BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...https://jrct.niph.go.jp/latest-detail/jRCT2031...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性Both1）\\t以下のいずれかによりプロトコール治療無効と判断された場合（無効中止）\\n\\r\\n①\\...NoneBRAF融合遺伝子、BRAF遺伝子再構成、低悪性度神経膠腫、膵癌BRAF fusion gene, BRAF rearrangement, low-grad...ビニメチニブとして1回45 mgを1日2回経口投与する。Binimetinib is administered 45 mg orally, twic...NaNNaN
23jRCT2041220125抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難...本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。https://jrct.niph.go.jp/latest-detail/jRCT2041...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneTeclistamab：被験者はteclistamab単剤療法を受ける。Teclistama...Teclistamab: Participants will receive teclist...NaNNaN
24jRCT2021220036MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-...本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお...https://jrct.niph.go.jp/latest-detail/jRCT2021...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneパート1 用量レベル1：エルラナタマブ，ダラツムマブ，レナリドミド\\n\\r\\nパート1 用量...Part 1 Dose Level 1:Elranatamab, Daratumumab, ...NaNNaN
25jRCT2063220071移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及...無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons...https://jrct.niph.go.jp/latest-detail/jRCT2063...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNone・A群（DVRd導入療法 + ASCT + DVRd地固め療法 + レナリドミド維持療法）\\...- Arm A (DVRd Induction + ASCT + DVRd Consolid...NaNNaN
26jRCT2021220022[M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB...再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ...https://jrct.niph.go.jp/latest-detail/jRCT2021...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNone1サイクルを28日間とし，ABBV-383（静脈内投与）とポマリドミド（経口）+デキサメタゾ...Participants will receive intravenous (IV) ABB...NaNNaN
27jRCT2033220220Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投...https://jrct.niph.go.jp/latest-detail/jRCT2033...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNoneCilta-cel：本試験は、先行試験でcilta-celの投与を受けた被験者に対する追跡調...Cilta-cel:Participants who had received cilta-...NaNNaN
28jRCT2031220060自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135...自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ...https://jrct.niph.go.jp/latest-detail/jRCT2031...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneElranatamab \\n\\r\\nBCMAおよびCD3を標的とする二重特異性抗体\\n\\r\\...Drug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an...NaNNaN
29jRCTs051220019再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)...https://jrct.niph.go.jp/latest-detail/jRCTs051...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性Both・BNCT実施の中止：\\n\\r\\n同意取得に到った後に、選択基準に背馳する事象、または除外基...None標準治療後の再発悪性神経膠腫の患者を対象に、サイクロトロン中性子照射システム（NeuCure...BNCT is performed in combination with a cyclot...介入研究Interventional
30jRCT2053220006製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ...本治験の主要目的は、不適合ide-celの安全性を評価することである。https://jrct.niph.go.jp/latest-detail/jRCT2053...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNoneide-celの添付文書、治験実施医療機関の通常診療慣行に従い、また担当医師の判断に基づき、...In accordance with the ide-cel prescribing inf...NaNNaN
31jRCT2031210635再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の...本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D...https://jrct.niph.go.jp/latest-detail/jRCT2031...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneダラツムマブ\\n\\r\\nA群:Teclistamab-ダラツムマブ（Tec-Dara）\\n\\...Daratumumab\\n\\r\\nArm A: Teclistamab-daratumuma...NaNNaN
32jRCT2031210607有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ...既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適...https://jrct.niph.go.jp/latest-detail/jRCT2031...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNone被験薬：Belantamab mafodotin（ヒト化抗BCMAモノクローナル抗体）\\n\\...Belantamab mafodotin (anti-BCMA (B-cell matura...NaNNaN
33jRCT2033210469デリタクト注使用成績比較調査使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的...https://jrct.niph.go.jp/latest-detail/jRCT2033......男性・女性BothNoneNaNNaN
34jRCTs071210084未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で...未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間...https://jrct.niph.go.jp/latest-detail/jRCTs071...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性Both1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次...None1. ダラツムマブ+レナリドミド+デキサメサゾン併用寛解導入療法 (DRD療法)\\n\\r\\n...1. Daratumumab + lenalidomide + dexamethasone ...介入研究Interventional
35jRCTs071210074未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別...未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療...https://jrct.niph.go.jp/latest-detail/jRCTs071...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性Both1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次...None1)寛解導入療法\\n\\r\\nDRD療法 1,2コース:Dara IV 16mg/kg or ...1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour...介入研究Interventional
36jRCT2031210299再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...https://jrct.niph.go.jp/latest-detail/jRCT2031...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNoneDSP-0390を1日1回経口投与する。1サイクルを28日間とし、安全性及び治療レスポンスを...Patients will receive DSP-0390 orally once dai...NaNNaN
37jRCT2011210025造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド...造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6...https://jrct.niph.go.jp/latest-detail/jRCT2011...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNoneA群\\n\\r\\n被験者は，ランダム化を行う前にボルテゾミブ，レナリドミド及びデキサメタゾン(...Arm A\\n\\r\\nParticipants will receive bortezomi...NaNNaN
38jRCT2051210043再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ...再発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber...https://jrct.niph.go.jp/latest-detail/jRCT2051...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性BothNone【IberDd】第1ステージにおいて、Iberdomide（CC-220）1.0mg、1.3...[IberDd] At the First Stage, Iberdomide (CC-22...NaNNaN
39jRCTs031200320JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋...高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ...https://jrct.niph.go.jp/latest-detail/jRCTs031...無作為化比較randomized controlled trial非盲検open(masking not used)実薬（治療）対照active control...男性・女性Both＜患者の中止について＞\\n\\r\\nD-MPB療法の中止規準\\n\\r\\n（1）\\tD-MPB療...None導入療法（A・B群共通）：D-MPB療法（3週1コースとして合計18コース行う）、第1コース...Induction therapy (both arm A and arm B) D-MPB...介入研究Interventional
40jRCT2033200278MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効...【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM...https://jrct.niph.go.jp/latest-detail/jRCT2033...単一群single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性BothNoneOPC-415 (上限1×10^7個/kg), 2日間投与\\nOPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\...NaNNaN
41jRCTs071190010悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩...https://jrct.niph.go.jp/latest-detail/jRCTs071...無作為化比較randomized controlled trial二重盲検double blindプラセボ対照placebo control...男性・女性BothCTCAE v4.0 Grade 1-2の場合は、メマンチン塩酸塩内服の継続・増量可とし、G...None膠芽腫、退形成性星細胞腫、退形成性乏突起膠腫gliobalastoma, anaplastic astrocytoma,anaplast...プロトコル治療は放射線照射療法の適用が決定次第、開始される。プロトコル治療の併用療法として、...1)Arm A: Patients randomly selected group have...介入研究Interventional
42jRCTs021180010塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法...悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del...https://jrct.niph.go.jp/latest-detail/jRCTs021...単一群single arm study非盲検open(masking not used)無治療対照/標準治療対照no treatment control/standard of care control...男性・女性Both以下のいずれかの場合プロトコール治療中止とする。\\n\\r\\n(ア)\\t後述する有害事象により...None脊髄腫瘍Spinal cord tumorACNU（0.25 mg/ml, 4ml）のCED法による脊髄髄内注入\\n\\r\\nテモゾロミ...ACNU delivery (0.25 mg/ml, 4ml) into the spin...介入研究Interventional
43jRCTs061180085初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、...初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施...https://jrct.niph.go.jp/latest-detail/jRCTs061...非無作為化比較single arm study非盲検open(masking not used)非対照uncontrolled control...男性・女性Both非血液毒性\\n\\r\\n1)試験薬投与後、投与前と比較して症状の悪化または臨床検査値の異常変動...None1）WT1-W10ペプチド癌ワクチン療法\\n\\r\\nWT1-W10ペプチド癌ワクチン療法とし...1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade...介入研究Interventional
44jRCTs031180170初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを...https://jrct.niph.go.jp/latest-detail/jRCTs031...単一群single arm study非盲検open(masking not used)ヒストリカルコントロールhistorical control...男性・女性Both症例登録の中止\\n\\r\\n1)原疾患の増悪\\n\\r\\n2)治療を中止すべき重篤な有害事象の発...None悪性神経膠腫Malignant gliomaVEGFR1およびVEGFR2ペプチド(各2mg)とIFA混合液の皮下投与。毎週投与８回後、...Subcutaneous injection of VEGFR1 and VEGFR2 pe...介入研究Interventional
\n", "

45 rows × 32 columns

\n", "
" ], "text/plain": [ " JRCT ID Title \\\n", "0 jRCT2051240141 新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO... \n", "1 jRCT2051240121 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n", "2 jRCT1031240239 JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学... \n", "3 jRCT2041240056 [M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する... \n", "4 jRCT2021240013 ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投... \n", "5 jRCT2031240090 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n", "6 jRCT2031240014 自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患... \n", "7 jRCT2041240003 再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と... \n", "8 jRCT2031230660 再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo... \n", "9 jRCT2021230055 CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ... \n", "10 jRCT2061230084 自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca... \n", "11 jRCT2071230097 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n", "12 jRCT2071230095 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n", "13 jRCT2011230049 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､... \n", "14 jRCT2051230108 再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93... \n", "15 jRCT2051230069 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n", "16 jRCT2031230223 新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe... \n", "17 jRCT2051230065 多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性... \n", "18 jRCT2031230087 再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特... \n", "19 jRCT2032230060 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n", "20 jRCT1070230005 迅速ウイルスPCR法によるウイルス感染症の早期診断 \n", "21 jRCT2031230009 先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ... \n", "22 jRCT2031230007 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n", "23 jRCT2041220125 抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難... \n", "24 jRCT2021220036 MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-... \n", "25 jRCT2063220071 移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及... \n", "26 jRCT2021220022 [M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB... \n", "27 jRCT2033220220 Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験 \n", "28 jRCT2031220060 自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135... \n", "29 jRCTs051220019 再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索 \n", "30 jRCT2053220006 製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ... \n", "31 jRCT2031210635 再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の... \n", "32 jRCT2031210607 有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ... \n", "33 jRCT2033210469 デリタクト注使用成績比較調査 \n", "34 jRCTs071210084 未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で... \n", "35 jRCTs071210074 未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別... \n", "36 jRCT2031210299 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n", "37 jRCT2011210025 造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド... \n", "38 jRCT2051210043 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ... \n", "39 jRCTs031200320 JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋... \n", "40 jRCT2033200278 MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効... \n", "41 jRCTs071190010 悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験 \n", "42 jRCTs021180010 塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法... \n", "43 jRCTs061180085 初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、... \n", "44 jRCTs031180170 初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験 \n", "\n", " 研究・治験の目的 \\\n", "0 H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20... \n", "1 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... \n", "2 手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を対象に、標準治... \n", "3 再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。 \n", "4 重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価すること \n", "5 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... \n", "6 本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並... \n", "7 Treatment \n", "8 本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単... \n", "9 再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法... \n", "10 自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法... \n", "11 再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480... \n", "12 再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ... \n", "13 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab... \n", "14 再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。 \n", "15 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n", "16 新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ... \n", "17 パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を... \n", "18 ・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54... \n", "19 初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交... \n", "20 ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1... \n", "21 本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による... \n", "22 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... \n", "23 本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。 \n", "24 本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお... \n", "25 無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons... \n", "26 再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ... \n", "27 この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投... \n", "28 自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ... \n", "29 BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)... \n", "30 本治験の主要目的は、不適合ide-celの安全性を評価することである。 \n", "31 本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D... \n", "32 既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適... \n", "33 使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的... \n", "34 未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間... \n", "35 未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療... \n", "36 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... \n", "37 造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6... \n", "38 再発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber... \n", "39 高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ... \n", "40 【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM... \n", "41 悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩... \n", "42 悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del... \n", "43 初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施... \n", "44 初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを... \n", "\n", " URL 無作為化 \\\n", "0 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n", "1 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n", "2 https://jrct.niph.go.jp/latest-detail/jRCT1031... 無作為化比較 \n", "3 https://jrct.niph.go.jp/latest-detail/jRCT2041... 単一群 \n", "4 https://jrct.niph.go.jp/latest-detail/jRCT2021... 単一群 \n", "5 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n", "6 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n", "7 https://jrct.niph.go.jp/latest-detail/jRCT2041... 単一群 \n", "8 https://jrct.niph.go.jp/latest-detail/jRCT2031... 非無作為化比較 \n", "9 https://jrct.niph.go.jp/latest-detail/jRCT2021... 無作為化比較 \n", "10 https://jrct.niph.go.jp/latest-detail/jRCT2061... 無作為化比較 \n", "11 https://jrct.niph.go.jp/latest-detail/jRCT2071... 無作為化比較 \n", "12 https://jrct.niph.go.jp/latest-detail/jRCT2071... 無作為化比較 \n", "13 https://jrct.niph.go.jp/latest-detail/jRCT2011... 単一群 \n", "14 https://jrct.niph.go.jp/latest-detail/jRCT2051... 単一群 \n", "15 https://jrct.niph.go.jp/latest-detail/jRCT2051... 単一群 \n", "16 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n", "17 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n", "18 https://jrct.niph.go.jp/latest-detail/jRCT2031... 非無作為化比較 \n", "19 https://jrct.niph.go.jp/latest-detail/jRCT2032... 単一群 \n", "20 https://jrct.niph.go.jp/latest-detail/jRCT1070... \n", "21 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n", "22 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n", "23 https://jrct.niph.go.jp/latest-detail/jRCT2041... 無作為化比較 \n", "24 https://jrct.niph.go.jp/latest-detail/jRCT2021... 無作為化比較 \n", "25 https://jrct.niph.go.jp/latest-detail/jRCT2063... 無作為化比較 \n", "26 https://jrct.niph.go.jp/latest-detail/jRCT2021... 単一群 \n", "27 https://jrct.niph.go.jp/latest-detail/jRCT2033... 単一群 \n", "28 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n", "29 https://jrct.niph.go.jp/latest-detail/jRCTs051... 単一群 \n", "30 https://jrct.niph.go.jp/latest-detail/jRCT2053... 単一群 \n", "31 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n", "32 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n", "33 https://jrct.niph.go.jp/latest-detail/jRCT2033... \n", "34 https://jrct.niph.go.jp/latest-detail/jRCTs071... 単一群 \n", "35 https://jrct.niph.go.jp/latest-detail/jRCTs071... 単一群 \n", "36 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n", "37 https://jrct.niph.go.jp/latest-detail/jRCT2011... 無作為化比較 \n", "38 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n", "39 https://jrct.niph.go.jp/latest-detail/jRCTs031... 無作為化比較 \n", "40 https://jrct.niph.go.jp/latest-detail/jRCT2033... 単一群 \n", "41 https://jrct.niph.go.jp/latest-detail/jRCTs071... 無作為化比較 \n", "42 https://jrct.niph.go.jp/latest-detail/jRCTs021... 単一群 \n", "43 https://jrct.niph.go.jp/latest-detail/jRCTs061... 非無作為化比較 \n", "44 https://jrct.niph.go.jp/latest-detail/jRCTs031... 単一群 \n", "\n", " allocation 盲検化 masking \\\n", "0 randomized controlled trial 二重盲検 double blind \n", "1 randomized controlled trial 非盲検 open(masking not used) \n", "2 randomized controlled trial 非盲検 open(masking not used) \n", "3 single arm study 非盲検 open(masking not used) \n", "4 single arm study 非盲検 open(masking not used) \n", "5 randomized controlled trial 非盲検 open(masking not used) \n", "6 randomized controlled trial 非盲検 open(masking not used) \n", "7 single arm study 非盲検 open(masking not used) \n", "8 non-randomized controlled trial 非盲検 open(masking not used) \n", "9 randomized controlled trial 非盲検 open(masking not used) \n", "10 randomized controlled trial 非盲検 open(masking not used) \n", "11 randomized controlled trial 非盲検 open(masking not used) \n", "12 randomized controlled trial 非盲検 open(masking not used) \n", "13 single arm study 非盲検 open(masking not used) \n", "14 single arm study 非盲検 open(masking not used) \n", "15 single arm study 非盲検 open(masking not used) \n", "16 randomized controlled trial 非盲検 open(masking not used) \n", "17 randomized controlled trial 非盲検 open(masking not used) \n", "18 non-randomized controlled trial 非盲検 open(masking not used) \n", "19 single arm study 非盲検 open(masking not used) \n", "20 \n", "21 single arm study 非盲検 open(masking not used) \n", "22 single arm study 非盲検 open(masking not used) \n", "23 randomized controlled trial 非盲検 open(masking not used) \n", "24 randomized controlled trial 非盲検 open(masking not used) \n", "25 randomized controlled trial 非盲検 open(masking not used) \n", "26 single arm study 非盲検 open(masking not used) \n", "27 single arm study 非盲検 open(masking not used) \n", "28 randomized controlled trial 非盲検 open(masking not used) \n", "29 single arm study 非盲検 open(masking not used) \n", "30 single arm study 非盲検 open(masking not used) \n", "31 randomized controlled trial 非盲検 open(masking not used) \n", "32 single arm study 非盲検 open(masking not used) \n", "33 \n", "34 single arm study 非盲検 open(masking not used) \n", "35 single arm study 非盲検 open(masking not used) \n", "36 single arm study 非盲検 open(masking not used) \n", "37 randomized controlled trial 非盲検 open(masking not used) \n", "38 randomized controlled trial 非盲検 open(masking not used) \n", "39 randomized controlled trial 非盲検 open(masking not used) \n", "40 single arm study 非盲検 open(masking not used) \n", "41 randomized controlled trial 二重盲検 double blind \n", "42 single arm study 非盲検 open(masking not used) \n", "43 single arm study 非盲検 open(masking not used) \n", "44 single arm study 非盲検 open(masking not used) \n", "\n", " 対照 control ... 性別 \\\n", "0 プラセボ対照 placebo control ... \n", "1 実薬（治療）対照 active control ... \n", "2 実薬（治療）対照 active control ... 男性・女性 \n", "3 非対照 uncontrolled control ... \n", "4 非対照 uncontrolled control ... 男性・女性 \n", "5 無治療対照/標準治療対照 no treatment control/standard of care control ... 男性・女性 \n", "6 実薬（治療）対照 active control ... 男性・女性 \n", "7 非対照 uncontrolled control ... 男性・女性 \n", "8 非対照 uncontrolled control ... 男性・女性 \n", "9 実薬（治療）対照 active control ... 男性・女性 \n", "10 実薬（治療）対照 active control ... 男性・女性 \n", "11 実薬（治療）対照 active control ... 男性・女性 \n", "12 実薬（治療）対照 active control ... 男性・女性 \n", "13 非対照 uncontrolled control ... 男性・女性 \n", "14 非対照 uncontrolled control ... 男性・女性 \n", "15 非対照 uncontrolled control ... 男性・女性 \n", "16 実薬（治療）対照 active control ... 男性・女性 \n", "17 実薬（治療）対照 active control ... 男性・女性 \n", "18 非対照 uncontrolled control ... 男性・女性 \n", "19 非対照 uncontrolled control ... 男性・女性 \n", "20 ... 男性・女性 \n", "21 非対照 uncontrolled control ... 男性・女性 \n", "22 非対照 uncontrolled control ... 男性・女性 \n", "23 実薬（治療）対照 active control ... 男性・女性 \n", "24 実薬（治療）対照 active control ... 男性・女性 \n", "25 実薬（治療）対照 active control ... 男性・女性 \n", "26 非対照 uncontrolled control ... 男性・女性 \n", "27 非対照 uncontrolled control ... 男性・女性 \n", "28 実薬（治療）対照 active control ... 男性・女性 \n", "29 非対照 uncontrolled control ... 男性・女性 \n", "30 非対照 uncontrolled control ... 男性・女性 \n", "31 実薬（治療）対照 active control ... 男性・女性 \n", "32 非対照 uncontrolled control ... 男性・女性 \n", "33 ... 男性・女性 \n", "34 非対照 uncontrolled control ... 男性・女性 \n", "35 非対照 uncontrolled control ... 男性・女性 \n", "36 非対照 uncontrolled control ... 男性・女性 \n", "37 実薬（治療）対照 active control ... 男性・女性 \n", "38 実薬（治療）対照 active control ... 男性・女性 \n", "39 実薬（治療）対照 active control ... 男性・女性 \n", "40 非対照 uncontrolled control ... 男性・女性 \n", "41 プラセボ対照 placebo control ... 男性・女性 \n", "42 無治療対照/標準治療対照 no treatment control/standard of care control ... 男性・女性 \n", "43 非対照 uncontrolled control ... 男性・女性 \n", "44 ヒストリカルコントロール historical control ... 男性・女性 \n", "\n", " Gender 中止基準 \\\n", "0 \n", "1 \n", "2 Both ＜患者の中止について＞\\n\\r\\n(1) プロトコール治療無効と判断\\n\\r\\n(2) 有害... \n", "3 \n", "4 Both \n", "5 Both 1）プロトコール治療無効と判断された場合（無効中止）\\n\\r\\n2）\\t有害事象によりプロト... \n", "6 Both \n", "7 Both \n", "8 Both \n", "9 Both \n", "10 Both \n", "11 Both \n", "12 Both \n", "13 Both \n", "14 Both \n", "15 Both 1) 投与継続が困難な有害事象が発現した場合\\t\\n\\r\\n2) 治験開始後... \n", "16 Both \n", "17 Both \n", "18 Both \n", "19 Both 以下のいずれかの場合、プロトコール治療（テモゾロミド維持療法6サイクル及びHeadG2）を中... \n", "20 Both \n", "21 Both \n", "22 Both 1）\\t以下のいずれかによりプロトコール治療無効と判断された場合（無効中止）\\n\\r\\n①\\... \n", "23 Both \n", "24 Both \n", "25 Both \n", "26 Both \n", "27 Both \n", "28 Both \n", "29 Both ・BNCT実施の中止：\\n\\r\\n同意取得に到った後に、選択基準に背馳する事象、または除外基... \n", "30 Both \n", "31 Both \n", "32 Both \n", "33 Both \n", "34 Both 1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次... \n", "35 Both 1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次... \n", "36 Both \n", "37 Both \n", "38 Both \n", "39 Both ＜患者の中止について＞\\n\\r\\nD-MPB療法の中止規準\\n\\r\\n（1）\\tD-MPB療... \n", "40 Both \n", "41 Both CTCAE v4.0 Grade 1-2の場合は、メマンチン塩酸塩内服の継続・増量可とし、G... \n", "42 Both 以下のいずれかの場合プロトコール治療中止とする。\\n\\r\\n(ア)\\t後述する有害事象により... \n", "43 Both 非血液毒性\\n\\r\\n1)試験薬投与後、投与前と比較して症状の悪化または臨床検査値の異常変動... \n", "44 Both 症例登録の中止\\n\\r\\n1)原疾患の増悪\\n\\r\\n2)治療を中止すべき重篤な有害事象の発... \n", "\n", " Discontinuation Criteria 対象疾患キーワード \\\n", "0 None \n", "1 None \n", "2 None \n", "3 None \n", "4 None \n", "5 None 膠芽腫、grade 3・4星細胞腫、grade 3乏突起膠腫 \n", "6 None \n", "7 None \n", "8 None \n", "9 None \n", "10 None \n", "11 None \n", "12 None \n", "13 None \n", "14 None \n", "15 None \n", "16 None \n", "17 None \n", "18 None \n", "19 None 神経膠腫 \n", "20 None 白血病、悪性リンパ腫、多発性骨髄腫、再生不良性貧血、骨髄異形成症候群 \n", "21 None \n", "22 None BRAF融合遺伝子、BRAF遺伝子再構成、低悪性度神経膠腫、膵癌 \n", "23 None \n", "24 None \n", "25 None \n", "26 None \n", "27 None \n", "28 None \n", "29 None \n", "30 None \n", "31 None \n", "32 None \n", "33 None \n", "34 None \n", "35 None \n", "36 None \n", "37 None \n", "38 None \n", "39 None \n", "40 None \n", "41 None 膠芽腫、退形成性星細胞腫、退形成性乏突起膠腫 \n", "42 None 脊髄腫瘍 \n", "43 None \n", "44 None 悪性神経膠腫 \n", "\n", " Keyword \\\n", "0 \n", "1 \n", "2 \n", "3 \n", "4 \n", "5 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "6 \n", "7 \n", "8 \n", "9 \n", "10 \n", "11 \n", "12 \n", "13 \n", "14 \n", "15 \n", "16 \n", "17 \n", "18 \n", "19 Glioma \n", "20 Leukemia, malignant lymphoma, multiple myeloma... \n", "21 \n", "22 BRAF fusion gene, BRAF rearrangement, low-grad... \n", "23 \n", "24 \n", "25 \n", "26 \n", "27 \n", "28 \n", "29 \n", "30 \n", "31 \n", "32 \n", "33 \n", "34 \n", "35 \n", "36 \n", "37 \n", "38 \n", "39 \n", "40 \n", "41 gliobalastoma, anaplastic astrocytoma,anaplast... \n", "42 Spinal cord tumor \n", "43 \n", "44 Malignant glioma \n", "\n", " 介入の内容 \\\n", "0 被験者は、ベースラインでONC201週2回投与群、ONC201週1回投与群又はプラセボ投与群... \n", "1 薬物　アベマシクリブ\\n\\r\\n経口投与\\n\\r\\nその他の名称 LY2835219\\n\\r... \n", "2 A群：標準治療群[術後化学放射線療法]/ B群：試験治療群[Watch & Wait... \n", "3 投与群：ABBV-383用量A\\n\\r\\nABBV-383の用量Aを151週間の試験期間中に... \n", "4 サバトリマブ（MBG453）：静脈内投与\\n\\r\\nアザシチジン：皮下投与又は静脈内投与\\n... \n", "5 A群：BPC療法\\n\\r\\n悪性神経膠腫に対して保険適用されている化学療法から患者の状態に合... \n", "6 Teclistamab -\\n\\r\\nTeclistamab，ダラツムマブ皮下投与製剤及びレ... \n", "7 AZD0305 を3週毎に静脈内投与する\\n \n", "8 cevostamab：Cevostamabは、1サイクルを28日間として2週間隔、4週間隔に... \n", "9 エルラナタマブ（投与経路：皮下）\\n\\r\\nエロツズマブ（投与経路：静脈内）\\n\\r\\nポマ... \n", "10 A群\\n\\r\\n製品：イデカブタゲン　ビクルユーセル\\n\\r\\n規定用量を規定された日に投与... \n", "11 [日本人コホート] \\n\\r\\nMezigdomide/ボルテゾミブ/デキサメタゾン\\n\\r... \n", "12 A群：Mezigdomide、カルフィルゾミブ、デキサメタゾン\\n\\r\\nB群：カルフィルゾ... \n", "13 治験治療、自家末梢血幹細胞採取および移植、血液検査、骨髄検査等 \n", "14 CC-93269 \n", "15 ＜コホート1＞\\n\\r\\nロムスチン130 mg/m2を6週間ごとに経⼝投与する。\\n\\r\\... \n", "16 A1群: Iberdomide 用量 1レベル\\n\\r\\nA2群: Iberdomide 用... \n", "17 パート1:\\n\\r\\n被験薬：Belantamab\\n\\r\\n被験薬：ベランタマブ　マホドチ... \n", "18 被験薬: REGN5458静脈内投与\\n\\r\\n第II相: 疾患進行が認められるまで、又はそ... \n", "19 本品を使用する患者は、頭髪をすべて剃り、TTF ジェネレーターに接続した４枚のINE トラン... \n", "20 \n", "21 薬剤：イサツキシマブ IV（SAR650984）\\n\\r\\n　剤形：バイアル、投与経路：静脈... \n", "22 ビニメチニブとして1回45 mgを1日2回経口投与する。 \n", "23 Teclistamab：被験者はteclistamab単剤療法を受ける。Teclistama... \n", "24 パート1 用量レベル1：エルラナタマブ，ダラツムマブ，レナリドミド\\n\\r\\nパート1 用量... \n", "25 ・A群（DVRd導入療法 + ASCT + DVRd地固め療法 + レナリドミド維持療法）\\... \n", "26 1サイクルを28日間とし，ABBV-383（静脈内投与）とポマリドミド（経口）+デキサメタゾ... \n", "27 Cilta-cel：本試験は、先行試験でcilta-celの投与を受けた被験者に対する追跡調... \n", "28 Elranatamab \\n\\r\\nBCMAおよびCD3を標的とする二重特異性抗体\\n\\r\\... \n", "29 標準治療後の再発悪性神経膠腫の患者を対象に、サイクロトロン中性子照射システム（NeuCure... \n", "30 ide-celの添付文書、治験実施医療機関の通常診療慣行に従い、また担当医師の判断に基づき、... \n", "31 ダラツムマブ\\n\\r\\nA群:Teclistamab-ダラツムマブ（Tec-Dara）\\n\\... \n", "32 被験薬：Belantamab mafodotin（ヒト化抗BCMAモノクローナル抗体）\\n\\... \n", "33 \n", "34 1. ダラツムマブ+レナリドミド+デキサメサゾン併用寛解導入療法 (DRD療法)\\n\\r\\n... \n", "35 1)寛解導入療法\\n\\r\\nDRD療法 1,2コース:Dara IV 16mg/kg or ... \n", "36 DSP-0390を1日1回経口投与する。1サイクルを28日間とし、安全性及び治療レスポンスを... \n", "37 A群\\n\\r\\n被験者は，ランダム化を行う前にボルテゾミブ，レナリドミド及びデキサメタゾン(... \n", "38 【IberDd】第1ステージにおいて、Iberdomide（CC-220）1.0mg、1.3... \n", "39 導入療法（A・B群共通）：D-MPB療法（3週1コースとして合計18コース行う）、第1コース... \n", "40 OPC-415 (上限1×10^7個/kg), 2日間投与\\n \n", "41 プロトコル治療は放射線照射療法の適用が決定次第、開始される。プロトコル治療の併用療法として、... \n", "42 ACNU（0.25 mg/ml, 4ml）のCED法による脊髄髄内注入\\n\\r\\nテモゾロミ... \n", "43 1）WT1-W10ペプチド癌ワクチン療法\\n\\r\\nWT1-W10ペプチド癌ワクチン療法とし... \n", "44 VEGFR1およびVEGFR2ペプチド(各2mg)とIFA混合液の皮下投与。毎週投与８回後、... \n", "\n", " Intervention(s) 試験の種類 Study Type \n", "0 Participants will be randomized at baseline in... NaN NaN \n", "1 Drug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r... NaN NaN \n", "2 Group A: Standard treatment group [Adjuvant ch... 介入研究 Interventional \n", "3 Experimental: ABBV-383 Dose A\\n\\r\\nParticipant... NaN NaN \n", "4 Sabatolimab (MBG453): Solution for intravenous... NaN NaN \n", "5 Group A: BPC Therapy\\n\\r\\nDepending on the pat... NaN NaN \n", "6 Teclistamab-Teclistamab, Daratumumab SC, Lenal... NaN NaN \n", "7 AZD0305 IV every 3 weeks\\n NaN NaN \n", "8 cevostamab: Cevostamab will be administered in... NaN NaN \n", "9 Drug: Elranatamab\\n\\r\\nElranatamab will be adm... NaN NaN \n", "10 ArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n... NaN NaN \n", "11 [Japan safety lead-in cohort]\\n\\r\\nMezigdomide... NaN NaN \n", "12 Arm A: Mezigdomide, Carfilzomib and Dexamethas... NaN NaN \n", "13 Study treatment,Autologous Peripheral Blood St... NaN NaN \n", "14 CC-93269 NaN NaN \n", "15 <cohort1>\\n\\r\\nLomustine 130 mg/m2 orall... NaN NaN \n", "16 Arm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom... NaN NaN \n", "17 Part1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant... NaN NaN \n", "18 Drug: REGN5458 administered by intravenous (IV... NaN NaN \n", "19 The patient using the product should shave all... NaN NaN \n", "20 観察研究 Observational \n", "21 Drug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace... NaN NaN \n", "22 Binimetinib is administered 45 mg orally, twic... NaN NaN \n", "23 Teclistamab: Participants will receive teclist... NaN NaN \n", "24 Part 1 Dose Level 1:Elranatamab, Daratumumab, ... NaN NaN \n", "25 - Arm A (DVRd Induction + ASCT + DVRd Consolid... NaN NaN \n", "26 Participants will receive intravenous (IV) ABB... NaN NaN \n", "27 Cilta-cel:Participants who had received cilta-... NaN NaN \n", "28 Drug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an... NaN NaN \n", "29 BNCT is performed in combination with a cyclot... 介入研究 Interventional \n", "30 In accordance with the ide-cel prescribing inf... NaN NaN \n", "31 Daratumumab\\n\\r\\nArm A: Teclistamab-daratumuma... NaN NaN \n", "32 Belantamab mafodotin (anti-BCMA (B-cell matura... NaN NaN \n", "33 NaN NaN \n", "34 1. Daratumumab + lenalidomide + dexamethasone ... 介入研究 Interventional \n", "35 1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour... 介入研究 Interventional \n", "36 Patients will receive DSP-0390 orally once dai... NaN NaN \n", "37 Arm A\\n\\r\\nParticipants will receive bortezomi... NaN NaN \n", "38 [IberDd] At the First Stage, Iberdomide (CC-22... NaN NaN \n", "39 Induction therapy (both arm A and arm B) D-MPB... 介入研究 Interventional \n", "40 OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\... NaN NaN \n", "41 1)Arm A: Patients randomly selected group have... 介入研究 Interventional \n", "42 ACNU delivery (0.25 mg/ml, 4ml) into the spin... 介入研究 Interventional \n", "43 1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade... 介入研究 Interventional \n", "44 Subcutaneous injection of VEGFR1 and VEGFR2 pe... 介入研究 Interventional \n", "\n", "[45 rows x 32 columns]" ] }, "execution_count": 29, "metadata": {}, "output_type": "execute_result" } ], "source": [ "sorted_df" ] }, { "cell_type": "code", "execution_count": null, "metadata": {}, "outputs": [], "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }